Kornimate/medical-research-clean huggingface dataset:
daily single shot adductor canal block versus continuous adductor canal block after total knee arthroplasty

Conditions: Postoperative Pain

Summary: this study will compare the analgesic efficacy of daily single-shot adductor canal block(abc) versus continuous acb after total knee arthroplasty (tka).

patients 19-75 years old, of asa classification i-iii scheduled for unilateral tka, will be enrolled and randomized into two groups, single-shot acb group and continuous acb group. in both groups, participants will be administered a single-shot acb immediately after the end of the operation. the single-shot acb group will receive two separate single-shot acbs, on the first and second postoperative day. a nerve block catheter will be placed in patients in the continuous acb group, which will be connected to a patient-controlled analgesia pump until the second postoperative day. the primary outcome of this study is the average nrs pain score at rest from the end of surgery to 2 days after surgery.

Eligibility criteria:
inclusion criteria: * asa classification i, ii, iii * patients scheduled for unilateral knee arthroplasty exclusion criteria: * anesthesia other than spinal anesthesia * chronic opioid use * uncontrolled diabetes of hba1c\>7.5 * neuromuscular pathology of the ipsilateral leg * second-look knee arthroplasty * inability to communicate (e.g. dementia) * hypersensitivity to ropivacaine * bmi \> 40 * pregnancy
analgesia nociception index-guided anesthesia and standard anesthesia

Conditions: Gastric Cancer

Summary: the primary purpose of this study is to compare the analgesia nociception index-guided anesthesia and standard anesthesia on remifentanil requirement in desflurane anesthesia.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of gastric cancer exclusion criteria: * conversion to open laparotomy * prior opioid abuse * prior infection * cardiac arrythmia
evaluation of the bonfils fiberscope for predicted difficult intubation in awake patients with ear, nose, and throat (ent) cancer (invibo)

Conditions: Carcinoma

Summary: the bonfils intubation fiberscope (bf), a rigid medical device with a curved tip, is exclusively used in anesthesiology for orotracheal intubation (oti). the objective of the study was to evaluate the feasibility and the tolerance of an intubation procedure realized by means of the bf (bfi) in awake adult patients with predicted difficult intubation (pdi), in the context of ent cancer surgery. the intubation is performed under local anesthesia (either nasal, oral, or intercricothyroidal) and sedation using remifentanyl (aivoc) with spontaneous ventilation. the primary endpoint is the rate of bfi meeting quality requirements: the procedure must be both successful (≤ 2 attempts and duration \< 180 sec) and well tolerated (fahey score \< 2). the secondary endpoints include the difficulties met by the operator during the bfi and patient's perception of the intubation procedure, evaluated in the recovery room and 7 days after the intervention. sample size is calculated using a one-stage fleming design with p0=80%, p1=95%, alpha=5% and 80% power, for a total of 32 evaluable patients.


Eligibility criteria:
inclusion criteria: * male or female patients aged ≥ 18 years * requiring a surgical intervention for an ent carcinoma * presenting with a pdi defined either as an arne score \> 11, or a previous history of di or by the surgeon's judgment. * able to understand, read and write french * signed, written informed consent exclusion criteria: * impossible mask ventilation * patient with a laryngeal stridor indicative of upper airway stenosis * patient requiring an intubation by nasal route * glasgow score \< 12 * bmi \> 35 * pregnant or lactating women * documented history of cognitive or psychiatric disorders * difficult follow-up

Keywords: otolaryngology equipment and supplies intubation
abdominal wall local anesthesia to maximize postoperative pain control after cesarean delivery

Conditions: Postoperative Pain

Summary: this study has been designed to determine if women undergoing cesarean delivery with spinal anesthesia and routine pain management who also have an additional ultrasound guided transversus abdominis plane (tap)block using ropivacaine have better pain relief and a better quality of recovery than women who don't have the additional tap block. maximizing pain relief using ultrasound guided tap blocks in addition to neuraxial opioids, nsaids, and acetaminophen may improve acute pain outcomes, reduce adverse side effects, and potentially reduce chronic pain.


Eligibility criteria:
inclusion criteria: * non-emergent cd with planned spinal anesthesia * american society of anesthesia physical status class i \& ii * age ≥ 18 years * term gestational age (≥ 37 weeks) * english-speaking exclusion criteria: * morbid obesity (bmi³ 45 kg/m2) * laboring women * emergency cd * severe maternal cardiac disease * subjects with significant obstetric co-morbidities * failed spinal anesthesia * patient enrollment in another study involving medication within 30 days of cd * any other condition which may impair ability to cooperate with data collection * height less than 152 cm (5'0") * fetal anomalies or intrauterine fetal death

Keywords: cesarean, pain, transversus abdominus plane block
exercise program among lung cancer dyads

Conditions: Lung Cancer; Depression; Physical Activity; Quality of Life; Pain; Lung Cancer Symptoms

Summary: pilot study of an exercise program among patients with all stages of lung cancer examining feasibility and acceptability. preliminary outcomes include objective measures of physical function, depression, adherence to lung cancer treatments, quality of life (qol), and social support.

primary objective: i. determine the feasibility and acceptability of a progressive exercise program initiated after lung cancer diagnosis among patient partner dyads. secondary objective: i. examine the preliminary effects of partnered exercise on physical function, depression, adherence to lung cancer treatments, qol and social support . outline: participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. participants also attend home-based unsupervised exercise sessions via an instructional dvd once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.

Eligibility criteria:
inclusion criteria: * mild depression symptoms * able to participate in exercise program per physician approval * available partner/spouse to participate with patient exclusion criteria: * persistent severe depression symptoms * inability to participate in exercise * life expectancy less than 1 year
flna in hcc patients

Conditions: Hepatocellular Carcinoma

Summary: the risk of recurrence after hepatectomy for hepatocellular carcinoma (hcc) is very high. having a predictive marker of early recurrence (er) would be desirable to personalize the follow-up and possibly develop new targeted therapy. the aim of this study was to test the expression of filamin a (flna) in a cohort of patients operated for hcc.

a consecutive cohort of resected hcc patients will be analyzed. several different prognostic factors, including flna expression, will be tested against the risk of er. flna expression will be analyzed with immunohistochemistry in the intra-tumoral and extra-tumoral tissue compartments using a dedicated tissue microarray.

Eligibility criteria:
inclusion criteria: * the inclusion criteria were represented by the histological positivity for hcc with complete clinical, surgical, pathological, and follow-up data. exclusion criteria: * patients preoperatively treated with chemotherapy or trans-arterial therapy were excluded. * similarly, patients operated for recurrent hcc or with non-radical surgery or with missing data were excluded.
the antigagging effect of granisetron (kytril), an antiemetic drug, in dental situations

Conditions: Antiggaging Effect; Antiemetic; Granisetron; Gag Reflex; Dental Situations

Summary: antigagging effect of kytril (granisetron) an antiemetic drug in dental situations gagging in dental situations can be a problem to the patient and the operating dentist. there are not proven methods of eliminating this reflex which sometimes will not allow routine quality dental care. pharmacological and behavioral approaches to eliminate this reflex have been tried with limited success. this suggested study will test a potent antiemetic drug used in other clinical situations such as antineoplastic treatment. granisetron is a potential antagonist for the 5-hydroxytryptamine3-receptor - 5ht(3), the drug binds to the receptor and blocks the effect of nausea and vomiting. kytril mechanism of action was successfully proven for various medical situations as a potential antiemetic agent. our center for dental sedation and anesthesia in the oral medicine department have received approval to use granisetron as an antigagging drug in dental situations based on several pilot studies conducted in other medical centers in different clinical situations such as strabismus corrections, post hysterectomy and others. our preliminary clinical impression is that pre-emptive iv administration of this drug to patients with increased gag reflex is beneficial. in our research we try to investigate the possibility of using kytril in dental situations. in the first stage of this research we will study the intravenous use of this drug and its effects on normal subjects compare them to themselves with placebo. according to the results of this study we will go on to the second stage of the research and try the same drug under oral administration. the purpose of this study is to test the antigagging effect of this drug in a controlled manner in dental situations. our working hypothesis is that administration of this drug in dental situations with success, will allow many patients to receive good dental care


Eligibility criteria:
inclusion criteria: * normal subjects exclusion criteria: * presence of systemic disease * subjects under medication or drug or food complementary agents
utility of intra-operative image guidance system for missing metastases

Conditions: Colorectal Cancer; Metastatic to the Liver

Summary: intraoperatively, the surgeon will interrogate the liver with ultrasound. the time spent by the surgeon using the ultrasound is recorded. if all lesions seen on pre-op imaging were found, the patient does not have the pathfinder explorer system applied. if one or more lesions cannot be found, then the pathfinder explorer system is calibrated and a tracking device is attached to the ultrasound probe, which the surgeon will use to reattempt localization of the missing tumor. the pathfinder explorer system operates in real-time in conjunction with the ultrasound.


Eligibility criteria:
inclusion criteria: * patient has one or more colorectal liver metastases, at least one of which is ≤1.5cm in maximal diameter on pre-operative cross sectional imaging * undergoing liver resection and/or ablation exclusion criteria: * none
induced wound healing by application of expanded bone marrow stem cells in diabetic patients with critical limb ischemia

Conditions: Diabetic Foot

Summary: diabetic foot patients with chronic limb ischemia and without the option for surgical or interventional revascularization were recruited and randomized to the transplant groups or the control group within this clinical trial. these patients are randomized to control or intervention group, whereas the intervention is divided into bone marrow cells administered intramuscular or intraarterial or expanded bone marrow cells administered intramuscular or intraarterial resulting in five distinct groups. to measure the therapeutic effects of the various treatment arms patients were evaluated for (ankle brachial index (abi), transcutaneous oxygen partial pressure (tcpo2), and reactive hyperemia (blood oxygen level dependent \[bold\]). patients also underwent imaging with angiographic methods.

diabetic foot (df) is a concomitant illness of diabetes mellitus. diabetes is one of the main causes of non-traumatic amputation worldwide due to severe peripheral arterial occlusive disease with chronic critical limb ischemia being the most abundant problem. ulceration occurs as failure of oxygenation, nutrient supply and progressive occlusion of larger blood vessels often exacerbates pre-existing microvascular abnormalities. purified bone marrow mononuclear cells or expanded bone marrow cells enriched in cluster of differentiation 90+ (cd90+) mesenchymal stem cells (named tissue repair cells, \[trcs\]) are used in the treatment of diabetic ulcers in comparison to bone marrow derived stem cells to induce revascularization of the affected limb and to enhance local perfusion. cells are administered intramuscular or intraarterial. a control group of patients treated according national guidelines without stem cells serves as comparator. diabetic foot patients with chronic limb ischemia and without the option for surgical or interventional revascularization were recruited and randomized to the transplant groups or the control group within this clinical trial. to measure the therapeutic effects of the various treatment arms patients were evaluated for (ankle brachial index (abi), transcutaneous oxygen partial pressure (tcpo2), and reactive hyperemia (blood oxygen level dependent \[bold\]). patients also underwent imaging with angiographic methods.

Eligibility criteria:
inclusion criteria: * diabetes mellitus type 1 or 2 * peripheral occlusive arterial disease stage iii or iv (fontaine) with chronical ischemia, chronic foot ulcer, degree of severity \<5 (wagner), older than 6 weeks, without acute wound infection * ulcer size 1 - 30cm2, in case of osteomyelitis only one bone should be affected no trend towards healing in the ulcer after one week of standard treatment * angiopathic or angioneuropathic diabetic foot syndrome with no possible option of operative or interventional revascularisation * age 18 - 80 years * declaration of patient consent

Keywords: peripheral arterial occlusion disease (pad) diabetic foot critical limb ischemia (cli) stem cell therapy
home-based vision therapy

Conditions: Convergence Insufficiency

Summary: post-concussive vision symptoms affect many veterans who have experienced traumatic brain injury (tbi). one common issue is trouble with near vision, a problem that may persist long after the acute injury. double vision or difficulty focusing on close objects can affect reading and depth perception. poor reading can interfere with academic or work performance, and loss of near focusing can affect jobs that require fine motor tasks like machining and electrical work. even having trouble using a smartphone can have a substantial impact on both work and social function. near vision impairment after tbi is not well understood, and treatments are limited. the goal of this project is to investigate novel virtual-reality assessments and training games to improve the near vision diagnosis and home-based rehabilitation. restoring normal near vision function could have a large impact on the fulfillment of veterans' educational, career, and overall life goals.


Eligibility criteria:
inclusion criteria: * u.s. military veteran * place of residence within driving distance of cleveland, oh * clinical eye exam within 6 months prior to enrollment and since the most recent tbi (if applicable) and the onset of near vision symptoms (if applicable) * best-corrected visual acuity 20/25 or better in each eye * convergence insufficiency (vr-npc \< 32 deg) exclusion criteria: * neurological condition other than tbi that would affect convergence * history of strabismus, amblyopia, or other binocular vision issues prior to tbi

Keywords: vision, binocular convergence, ocular
group treatment for adolescents with depression

Conditions: Depression

Summary: youth with depressive symptoms are at risk for a range of problems later in life. this includes problematic interpersonal relationships, occupational stress, and the occurrence of adult mental disorders. the main purpose of this study is to test how effective two types of group therapy are at reducing depressive symptoms in youth. a focus on group therapy is important because group therapy allows for many youth to be treated in a short amount of time. group therapy is also helpful because youth can get social support and feel less alone in their symptoms when they participate in group. this study compares two groups, one that targets skills for managing difficult emotional experiences (dialectical behavior therapy skills group) and another group focuses on psychoeducation and is based on a publicly available treatment manual from the services for teens at risk (star) center at the university of pittsburgh. the results of this study will provide insights regarding the comparative efficacy of these two treatments, and regarding predictors of treatment response.


Eligibility criteria:
inclusion criteria: * english speaking * male or female, ages 14 to 19, all races and ethnicities * current depression as assessed by an alife - psr score equal to or greater than 4 * has a treating psychiatrist at sunnybrook health sciences centre exclusion criteria: * current manic episode * current psychosis
clinical evaluation, motor performance and quality of life in patients affected by soft tissue sarcomas, undergoing surgical treatment: observational study

Conditions: Sarcoma

Summary: the main aim of the study is evaluate quality of life and motor performance of patients with soft tissue sarcomas undergoing surgical treatment and post-operative rehabilitation treatment. primary objectives: * identification of clinical characteristics and motor damage after surgery for soft tissue sarcomas; * impact of perioperative treatments and surgery on the quality of life of patients with soft tissue sarcomas; * impact of post-operative rehabilitation treatment on quality of life and recovery of motor activity the primary endpoint will be the improvement in the toronto extremity salvage score (tess) between t1 (post-surgery) and t3 (at the end of rehabilitation treatment). secondary endpoints will be: 1. the evolution over the various timepoints of the selected rating scales (toronto extremity salvage score, musculoskeletal tumor society rating scale, numerical rating scale, brief pain questionnaire, douleur neuropathique en 4 questions, leeds assessment of neuropathic symptoms and signs scale, european organization for research and treatment of cancer, quality-of-life questionnaire (qlq)-c30, short form health survey 36); • the change in walking performance before and after the rehabilitation treatment.


Eligibility criteria:
inclusion criteria: - adult patients affected by primary localized soft tissue sarcoma, candidate to limb/trunk surgery with wide excision or retroperitoneal resection (including resection of the iliopsoas muscle with possible damage to the femoral nerve) with curative intent. exclusion criteria: * patients with recurrent tumors; * patients with metastatic disease; * patients with palliative surgery; * patients with amputations.
an immuno-therapy study of experimental medication bms-986205 given with nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage iv or recurrent non-small cell lung cancer

Conditions: Lung Cancer; Non-Small Cell Lung Cancer

Summary: this is a study of experimental medication bms-986205 given with nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage iv or recurrent non-small cell lung cancer.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * histologically confirmed stage iv nsclc per the 8th iaslc of squamous or nonsquamous histology * locally advanced disease with recurrence after chemoradiation therapy (stage iiib disease, specifically refers to patients with no curative treatment options) * no prior systemic anti-cancer therapy (including egfr and alk/ros1 inhibitors) given as primary therapy for advanced or metastatic disease * participants must have biomarker test results available for randomization * ecog performance status of ≤ 1 * measurable disease by ct or mri per recist 1.1 criteria exclusion criteria: * participants with known sensitizing egfr mutations or known alk/ros1 rearrangements * participants with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity * participants with an active, known or suspected autoimmune disease \[participants with type i diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll\] * participants with untreated cns metastases are excluded \[participants are eligible if cns metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the cns treatment) for at least 2 weeks prior to first treatment\] other protocol defined inclusion/exclusion criteria could apply